Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy

Table 4 Five-year actuarial rates of local-regional control according to clinical and pathologic disease status by molecular subtype

Factor	HR+/HER2- (n= 309)	HR+/HER2+ (n= 51)	HR-/HER2+ (n= 42)	HR-/HER2- (n= 193)	P-value
Clinical stage
I/II (n = 473)	98%	95%	86%	91%	0.004
III (n = 120)	92%	100%	89%	84%	0.25
Number positive nodes*
0 to 3 (n = 517)	98%	95%	89%	91%	0.007
≥ 4 (n = 75)	93%	100%	67%	56%	0.001
pCR
No (n = 471)	97%	95%	83%	84%	< 001
Yes (n = 124)	96%	100%	92%	99%	0.62
LVI
No (n = 500)	97%	95%	83%	93%	0.007
Yes (n = 95)	96%	100%	100%	70%	0.001
Nuclear grade**
1 or 2 (n = 197)	97%	100%	67%	100%	0.009
3 (n = 395)	97%	94%	88%	88%	0.04

* In three patients the number of lymph nodes was unknown. ** In one patient, the nuclear grade was unknown. LRC, local-regional control; LVI, lymphovascular invasion; pCR, pathologic complete response

ISSN: 1465-542X